Antigen Information

General Information of This Antigen
Antigen ID
TAR0MWTFE
Antigen Name
Nectin-4 (NECTIN4)
Gene Name
NECTIN4
Gene ID
81607
Synonym
Ig superfamily receptor LNIR;Nectin cell adhesion molecule 4;Poliovirus receptor-related protein 4
Sequence
MPLSLGAEMWGPEAWLLLLLLLASFTGRCPAGELETSDVVTVVLGQDAKLPCFYRGDSGE
QVGQVAWARVDAGEGAQELALLHSKYGLHVSPAYEGRVEQPPPPRNPLDGSVLLRNAVQA
DEGEYECRVSTFPAGSFQARLRLRVLVPPLPSLNPGPALEEGQGLTLAASCTAEGSPAPS
VTWDTEVKGTTSSRSFKHSRSAAVTSEFHLVPSRSMNGQPLTCVVSHPGLLQDQRITHIL
HVSFLAEASVRGLEDQNLWHIGREGAMLKCLSEGQPPPSYNWTRLDGPLPSGVRVDGDTL
GFPPLTTEHSGIYVCHVSNEFSSRDSQVTVDVLDPQEDSGKQVDLVSASVVVVGVIAALL
FCLLVVVVVLMSRYHRRKAQQMTQKYEEELTLTRENSIRRLHSHHTDPRSQPEESVGLRA
EGHPDSLKDNSSCSVMSEEPEGRSYSTLTTVREIETQTELLSPGSGRAEEEEDQDEGIKQ
AMNHFVQENGTLRAKPTGNGIYINGRGHLV

    Click to Show/Hide
Family
Nectin family
Function
Seems to be involved in cell adhesion through trans- homophilic and -heterophilic interactions, the latter including specifically interactions with NECTIN1. Does not act as receptor for alpha-herpesvirus entry into cells.

    Click to Show/Hide
Uniprot Entry
NECT4_HUMAN
HGNC ID
HGNC:19688
KEGG ID
hsa:81607
Each Antibody-drug Conjuate AND It's Component Related to This Antigen
Full List of The ADC Related to This Antigen
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
WO2022057651A1 ADC-19
WO2022057651A1 ADC-19 payload
Undisclosed
WO2022057651A1 ADC-19 linker
 [1]
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
WO2022057651A1 ADC-20
WO2022057651A1 ADC-20 payload
Undisclosed
WO2022057651A1 ADC-20 linker
 [1]
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
WO2022057651A1 ADC-21
WO2022057651A1 ADC-21 payload
Undisclosed
WO2022057651A1 ADC-21 linker
 [1]
Anti-NECTIN4 mAb
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
ADC2204
Undisclosed
Undisclosed
Undisclosed
 [2]
Enfortumab
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
Enfortumab vedotin
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 [3]
 ADC Info 
Araris ADC
Monomethyl auristatin E
Microtubule (MT)
Cathepsin B cleavable linker
 [4]
 ADC Info 
WO2022057651A1 ADC-22
WO2022057651A1 ADC-22 payload
Undisclosed
WO2022057651A1 ADC-22 linker
 [1]
Undisclosed
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
9MW-2821
Undisclosed
Undisclosed
Undisclosed
 [5]
 ADC Info 
BAT-8007
Undisclosed
Undisclosed
Undisclosed
 [6]
 ADC Info 
SHR-A2102
Undisclosed
Undisclosed
Undisclosed
 [7]
 ADC Info 
SKB-410
Undisclosed
Undisclosed
Undisclosed
 [8]
 ADC Info 
SYS6002
Undisclosed
Undisclosed
Undisclosed
 [9]
 ADC Info 
BA-3361
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 [10]
 ADC Info 
A-410
Undisclosed
Undisclosed
Undisclosed
 [11]
 ADC Info 
JS114
Undisclosed
Undisclosed
Undisclosed
 [12]
 ADC Info 
HLX-44
Undisclosed
Undisclosed
Undisclosed
 [13]
 ADC Info 
NTX-1105
Undisclosed
Undisclosed
Undisclosed
 [14]
 ADC Info 
ETX-22
Undisclosed
Undisclosed
Undisclosed
 [15]
 ADC Info 
N41mab-Val-Cit-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 [16]
 ADC Info 
Nectin-4 ADC (Jiangsu Hengrui)
Undisclosed
Undisclosed
Undisclosed
 [17]
 ADC Info 
SBT-6290
TLR8 agonist
Toll-like receptor 8 (TLR8)
Undisclosed
 [18]
References
Ref 1 Anti-nectin-4 antibody, conjugate including same, and application thereof; 2022-03-24.
Ref 2 Introduction to basic information on ADC drug ADC2204
Ref 3 Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med. 2021 Mar 25;384(12):1125-1135. doi: 10.1056/NEJMoa2035807.
Ref 4 Novel peptide linker-based nectin-4 targeting ADC shows improved tolerability with long-lasting anti-tumor efficacy at low doses. Cancer Res (2023) 83 (8_Supplement): LB221.
Ref 5 Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for treatment of Nectin-4-expressing Cancers. Mol Cancer Ther 2023 May MCT-22-0743.
Ref 6 Bio-Thera Solutions biopharmaceutical company product pipeline.
Ref 7 Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors; NCT05701709.
Ref 8 SKB410 for Injection in Solid Tumors; NCT05906537.
Ref 9 Antibody-drug conjugation SYS6002 receives clinical trial approval; 27 Oct 2022.
Ref 10 NextGen conditionally active biologic (CAB) anti-Nectin-4-ADC with improved stability and safety. Cancer Res (2023) 83 (7_Supplement): 1541.
Ref 11 Introduction to basic information on ADC drug A-410.
Ref 12 Junshi Biosciences biopharmaceutical company product pipeline
Ref 13 Introduction to basic information on ADC drug HLX-44.
Ref 14 Nectin therapeutics biotechnology company product pipeline
Ref 15 Emergence therapeutics product pipeline
Ref 16 Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer. Ann Oncol. 2017 Apr 1;28(4):769-776. doi: 10.1093/annonc/mdw678.
Ref 17 Introduction to basic information on Nectin-4 ADC (Jiangsu Hengrui).
Ref 18 SBT6290, a systemically administered Nectin-4-directed TLR8 ImmunoTAC (TM) therapeutic, is a potent human myeloid cell agonist for the treatment of Nectin-4-expressing tumors. Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-SITC2020.0712.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.